LDS/Medical Tests/MDMA, Urine

MDMA, Urine

3,4-Methylenedioxymethamphetamine (MDMA) is one of the class of drugs known as designer amphetamines and is a very potent CNS stimulant. MDMA acts as both a stimulant and as a psychedelic by producing either an energizing effect or distortions in time and perception. This particular drug is mostly abused by adolescents and young adults because it reduces inhibitions alongside increases in euphoria, feelings of closeness, empathy, and sexuality. MDMA is known on the street as Ecstasy. This drug contains mostly MDMA but also can contain other drugs in combination such as methamphetamine, ketamine, cocaine, dextromethorphan, ephedrine, and caffeine.

MDMA is mainly distributed in tablet form, but also may be distributed as capsules, powder, and liquid forms. Abuse of MDMA may produce the same effects as users of other stimulants such as cocaine and amphetamines, and produce physical effects such as increased motor activity, alertness, increase heart rate and blood pressure. High doses of MDMA can interfere with the ability to regulate body temperature, resulting in a sharp increase in body temperature (hyperthermia), leading to liver, kidney and cardiovascular failure.

MDMA is metabolized via the liver and excreted into the urine, allowing detection by various analytical methods such as Immunoassay (IA), Gas Chromatography/Mass spectroscopy (GC/MS), Liquid Chromatography/Mass Spectroscopy (LC/MS).

  • Drug abuse evaluation
  • Toxicity assessment
A qualitative positive result from an immunoassay (IA) test indicates only the presence of MDMA and does not necessarily correlate with the extent of physiological and psychological effects. Any positive result should be confirmed by a non-immunological method such as GC, GC/MS or LC/MS.

Therapeutic concentration: unknown
Toxic concentration: variable
Fatal concentration: variable

Note: therapeutic ranges and toxic thresholds are generally best evaluated from blood samples. Quantitative results obtained with blood samples collected at specific times after drug administration is preferred for pharmacokinetic analyses.

Cut-Off Ranges
Cut-off values are generally used to determine the positivity of the urine specimen being analyzed. Cut-off values can vary based on the particular method of analysis that is used for detection whether it is a qualitative method such as IA, or a quantitative method such as GC/MS or LC/MS. The testing laboratory cut-off range is listed on the patient report. Consult your physician for further information or click on one of the references that are listed below.

Immunoassay (IA), Gas Chromatography/Mass Spectroscopy (GC/MS), or Liquid Chromatography/Mass Spectroscopy (LC/MS). The main method of quantification is via LC/MS. This particular method of analysis can be used to detect various compounds such as MDMA. MDMA can be separated from biological specimens by liquid-liquid extraction or by solid-phase extraction. When analyzing urine specimens, a hydrolysis step may be required to free the parent drug and metabolites from glucuronide conjugates. Enzymatic hydrolysis is generally preferred over acid hydrolysis.

Fresh urine specimen collected in either a clean glass or plastic container. An acceptable urine specimen submitted for testing should be in the pH range of 3-11. Adulteration of the urine specimen can result in erroneous results.

Stability

  • Ambient: 3 days
  • Refrigeration: 14 days
  • Frozen: 14 days
Pharmacogenetic testing, such as genotyping *CYP1A2* and *CYP2D6,* which are partially responsible for metabolism of MDMA to MDA, may be useful. Supportive testing such as a liver profile, kidney profile, comprehensive metabolic panel, CBC, and testing for concomitant drugs may be appropriate.
1-3 days.
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
  • MDMA DEA Drug Fact Sheet.
  • Levine, Barry (Ed). Amphetamines/Sympathomimetic Amines. In: Principles of Forensic Toxicology, 4th Ed. Washington DC: AACC Press; 2013: 353-371.
  • Baselt RC (ed). Analytical procedures for therapeutic drug monitoring and emergency toxicology, 2nd ed. Littleton, MA: PSG Publishing Co.; 1987.
  • Baselt RC (ed). Disposition of toxic drugs and chemicals in man, 6th ed. Foster City, CA: Biomedical Publications; 2002.
  • Fitzgerald R. Analytical toxicology of the benzodiazepines. AACC Therapeutic Drug Monitoring and Toxicology. 1995;16(7):169-79.
  • Harman JG, Limbird LE, Molinoff PB, Ruddon RW, Gilman AG (eds). Goodman and Gilman’s the pharmacological basis of therapeutics, 9th ed. New York: McGraw-Hill Co.; 1996
  • Wians FH. Benzodiazepine update. AACC Therapeutic Drug Monitoring and Toxicology. 1989;11(4):7-20.
  • Zherdev VP, Caccia S, Garattini S, Ekonomov AL. Species differences in phenazepam kinetics and metabolism. Euro J Drug Metab Pharm. 1982;7:191-6.